Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation
作者: Viola W ZhuAlexa B SchrockThangavijayan BosemaniBryan S BennSiraj M AliSai-Hong Ignatius Ou
作者单位: 1University of California, Irvine School of Medicine
2Foundation Medicine, Inc.
3UC Irvine
4University of California Irvine School of Medicine
刊名: Lung Cancer: Targets and Therapy, 2018, Vol.2018 (default), pp.111-116
来源数据库: Dove Journal
DOI: 10.2147/LCTT.S186804
原始语种摘要: Anaplastic lymphoma kinase (ALK)-rearranged lung cancer defines a distinctive molecular cohort of patients whose outcomes are significantly improved by the availability of ALK inhibitors. Thus, it is imperative for clinicians to screen appropriate patients for this driver mutation with a molecular testing platform capable of capturing all ALK fusions. Here we report a novel VKORC1L1-ALK fusion and an ALK T1151K resistance mutation detected in a lung cancer patient who had been on crizotinib for over eight years. Alectinib induced a dramatic response in this patient demonstrating for the first time the clinical activity of alectinib against T1151K. This case illustrates the importance of performing repeat biopsy to explore mechanism(s) of resistance when patients experience disease...
全文获取路径: Dove 

  • mutation 变种
  • novel 长篇小说
  • fusion 融解
  • eight 
  • patient 有耐性的
  • whose 谁的
  • importance 重要性
  • platform 台地
  • imperative 命令
  • driver 驱动器传动装置